Platelet aggregation is one of the main functions of platelets, which are the smallest blood cells in the blood, accounting for 0.3% of the blood, and are one of the important components of blood. It maintains the integrity of the capillary wall in addition to accelerating clotting function. Malignant tumors enhance platelet aggregation. So what are the reasons for enhanced platelet aggregation? The following is an explanation. Etiology of enhanced platelet aggregation Various types of malignant tumors. The different mechanisms of tumor-induced platelet aggregation exist may be ADP-mediated: malignant tumor cells have activating substances that directly promote aggregation and can release ADP that mediates the aggregation reaction, ADP is formed spontaneously by the tumor or released by platelets; thrombus-dependent manner: some tumor cells have metastatic ability consistent with thrombus formation and platelet aggregation ability, and thrombus may be due to lipoproteins on the cell surface; thrombin generation The presence of plasma membrane proteins with platelet aggregation activity/procoagulant activity (PAA/PCA) in some tumor cells activates the coagulation system and leads to thrombin generation, which binds to the platelet surface to activate its secretion and platelet aggregation; tumor cell membrane glycoproteins: some membrane glycoproteins of tumor cells have been found to be involved in platelet aggregation in recent years, and membrane proteins mediate platelet aggregation in a thrombin-independent manner. However, they are susceptible to inhibition by trypsin. Among the above mechanisms, divalent cations and plasma factors are extremely important for the activity of platelet aggregation induced by tumor cells.